GlassScriptPhysician profile
Michael A Tavill
NPI 1417030792
$3,600.60
in general payments reported to CMS, 2019-2025
29 companies · $608 in 2025
The $608 reported for 2025 was more than what 81% of Pediatric Otolaryngology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $192 · 2021: $294 · 2022: $478 · 2023: $704 · 2024: $713 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974 · Consulting Fee: $50.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.82 |
| Consulting Fee | $50.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $565.84 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $455.24 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $303.76 | 2021-2025 | Hyqvia, Eohilia, Takhzyro |
| Alk-Abello, INC | $302.47 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Genzyme Corporation | $273.80 | 2019-2025 | |
| Optinose US, INC. | $242.88 | 2019-2024 | |
| Kaleo, INC. | $213.40 | 2019-2024 | Auvi-Q |
| Aerin Medical INC. | $169.39 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2024 | Airsupra |
| Acclarent, INC | $124.81 | 2019 | |
| Stryker Corporation | $118.83 | 2019-2022 | |
| Csl Behring | $118.08 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Octapharma USA, INC. | $103.88 | 2019-2024 | Cutaquig |
| Integra Lifesciences Corporation | $72.99 | 2019-2024 | Acclarent Aera |
| Bio Products Laboratory USA, INC. | $56.65 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $50.50 | 2024 | Ryaltris |
| Adma Biomanufacturing LLC | $50.22 | 2025 | |
| Shire North American Group INC | $44.08 | 2019 | |
| Aimmune Therapeutics, INC. | $27.36 | 2021-2022 | |
| Davol INC. | $26.87 | 2019 | |
| Inspire Medical Systems, INC. | $24.93 | 2024 | Inspire |
| Precigen, INC. | $20.18 | 2025 | |
| Genentech USA, INC. | $18.50 | 2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $18.08 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $16.54 | 2023 | |
| Incyte Corporation | $16.39 | 2021 | |
| Leo Pharma INC. | $14.87 | 2022 | |
| Cook Medical LLC | $14.08 | 2019 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tavill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.